A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient
Background Coronavirus disease 2019 (COVID-19) infection in lung transplant recipients can be lethal owing to the use of immunosuppressants. Antiviral agents may be administered to these patients. Co-packaged nirmatrelvir-ritonavir is a new agent currently being used in combination. Case presentation In this report, we present a case of a 64-year-old woman, a lung transplant recipient, who experienced hyponatremia and showed a high serum tacrolimus concentration following the administration of the co-packaged nirmatrelvir-ritonavir combination. Conclusion Although the nirmatrelvir-ritonavir and tacrolimus combination is not contraindicated, other treatment strategies should be considered first, if available, and the dose of tacrolimus should be reduced when using the nirmatrelvir-ritonavir combination. In cases where combination therapy is necessary, serum tacrolimus levels should be closely monitored in lung transplant recipients. Documentation of more such reports is important to identify drug interactions between nirmatrelvir-ritonavir and other agents, with the aim of preventing severe adverse effects..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Journal of cardiothoracic surgery - 19(2024), 1 vom: 15. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lo, Chien-Ming [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Antiviral agent |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s13019-024-02599-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055172822 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055172822 | ||
| 003 | DE-627 | ||
| 005 | 20240316064744.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240316s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13019-024-02599-w |2 doi | |
| 035 | |a (DE-627)SPR055172822 | ||
| 035 | |a (SPR)s13019-024-02599-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Lo, Chien-Ming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background Coronavirus disease 2019 (COVID-19) infection in lung transplant recipients can be lethal owing to the use of immunosuppressants. Antiviral agents may be administered to these patients. Co-packaged nirmatrelvir-ritonavir is a new agent currently being used in combination. Case presentation In this report, we present a case of a 64-year-old woman, a lung transplant recipient, who experienced hyponatremia and showed a high serum tacrolimus concentration following the administration of the co-packaged nirmatrelvir-ritonavir combination. Conclusion Although the nirmatrelvir-ritonavir and tacrolimus combination is not contraindicated, other treatment strategies should be considered first, if available, and the dose of tacrolimus should be reduced when using the nirmatrelvir-ritonavir combination. In cases where combination therapy is necessary, serum tacrolimus levels should be closely monitored in lung transplant recipients. Documentation of more such reports is important to identify drug interactions between nirmatrelvir-ritonavir and other agents, with the aim of preventing severe adverse effects. | ||
| 650 | 4 | |a Lung transplantation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tacrolimus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug interaction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antiviral agent |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nirmatrelvir-ritonavir |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Combination |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Chen, Wei-Hsun |4 aut | |
| 700 | 1 | |a Tsai, Meng-Yun |4 aut | |
| 700 | 1 | |a Lu, Hung-I |4 aut | |
| 700 | 1 | |a Hsiao, Yu-Hsin |4 aut | |
| 700 | 1 | |a Chuang, Kai-Hao |4 aut | |
| 700 | 1 | |a Chen, Yu |4 aut | |
| 700 | 1 | |a Wu, Hsuan-Feng |4 aut | |
| 700 | 1 | |a Huang, Kuo-Tung |4 aut | |
| 700 | 1 | |a Wang, Yi-Hsi |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiothoracic surgery |d BioMed Central, 2006 |g 19(2024), 1 vom: 15. März |w (DE-627)SPR02947129X |w (DE-600)2227224-0 |x 1749-8090 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g number:1 |g day:15 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13019-024-02599-w |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2024 |e 1 |b 15 |c 03 | ||